Sarah Bocchini

Sarah Bocchini

Auto-generated profile, based on publicly available information

Sarah Bocchini

Endocrinology and Diabetology Unit, Bambino Gesù Children's Hospital, IRCCS , Rome 00146

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
ACAntonino Crinò
Antonino Crinò
DFDanilo Fintini
Danilo Fintini
SBSarah Bocchini
Sarah Bocchini
GGGraziano Grugni
Graziano Grugni
Prader–Willi syndrome (PWS) is a complex multisystem disorder due to the absent expression of the paternally active genes in the PWS critical region on chromosome 15 (15q11.2-q13). The syndrome is considered the most common genetic cause of obesity, occurring in 1:10,000–1:30,000 live births. Its main characteristics include neonatal hypotonia, poor feeding, and lack of appetite in infancy, followed by weight gain, lack of satiety, and uncontrolled appetite, frequently after the age of 2–3 years. The clinical picture includes short stature, multiple endocrine abnormalities (hypogonadism, growth hormone/insulin-like growth factor-I axis dysfunction, hypothyroidism, central adrenal insufficiency), dysmorphic features, scoliosis, osteoporosis, mental retardation, and behavioral and psychiatric problems. Subjects with PWS will become severely obese unless their food intake is strictly controlled. Constant and obsessive food seeking behavior can make life very difficult for both the family and caretakers. Prevention of obesity is mandatory in these patients from the first years of life, because once obesity develops it is difficult to maintain the control of food intake. In fact, PWS subjects die prematurely from complications conventionally related to obesity, including diabetes mellitus, metabolic syndrome, sleep apnea, respiratory insufficiency, and cardiovascular disease. The mechanisms underlying hyperphagia in PWS are not completely known, and to date no drugs have proven their efficacy in controlling appetite. Consequently, dietary restriction, physical activity, and behavior management are fundamental in the prevention and management of obesity in PWS. In spite of all available therapeutic tools, however, successful weight loss and maintenance are hardly accomplished. In this context, clinical trials with new drugs have been initiated in order to find new possibilities of a therapy for obesity in these patients. The preliminary results of these studies seem to be encouraging. On the other hand, until well-proven medical treatments are available, bariatric surgery can be taken into consideration, especially in PWS patients with life-threatening comorbidities.

1 October 2019 in Growth Hormone & IGF Research
Verified
Journal Article
Closed access
VPViviana Valeria Palmieri
Viviana Valeria Palmieri
ALAntonella Lonero
Antonella Lonero
SBSarah Bocchini
Sarah Bocchini
GCGilda Cassano
Gilda Cassano
ACAlessio Convertino
Alessio Convertino
Maurizio DelvecchioMaurizio Delvecchio
Maurizio Delvecchio

25 May 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
AAAlessia Aureli
Alessia Aureli
FCFrancesco Carlomagno
Francesco Carlomagno
ACAntonino Crinò
Antonino Crinò
SBSarah Bocchini
Sarah Bocchini
SBSonia Battaglia
Sonia Battaglia
DFDanilo Fintini
Danilo Fintini
Objective: To evaluate the long-term effectiveness of laparoscopic sleeve gastrectomy (LSG) in pediatric and transition age patients with Prader–Willi syndrome (PWS). Design: Single-center, longitudinal, retrospective cohort study. Methods: We reviewed the electronic health records of 110 patients with PWS and 268 subjects undergoing LSG. We included 16 patients with PWS and severe obesity (PWS-LSG) and 32 matched non-syndromic patients with obesity (OB-LSG), both undergoing LSG, and 16 patients with PWS receiving lifestyle intervention only (PWS-LS). The primary endpoint was ΔBMI-SDS% at 5 years. Results: In PWS-LSG, BMI-SDS decreased from 5.18 to an early nadir at 1-2 years (median ΔBMI-SDS% ∼−26%), then partially rebounded to 4.75 at 5 years, with ΔBMI-SDS% −16.9% (P = .012). Conventional metrics confirmed this attenuated response, with %BMI change −2.8% and absolute ΔBMI-SDS −1.10 at 5 years. In OB-LSG, BMI-SDS declined from 4.95 to 2.24, with larger and more sustained improvement (ΔBMI-SDS% −57.4%; P < .001 within-group; P = .002 vs PWS-LSG), corresponding to a %BMI change −40.1% and absolute ΔBMI-SDS −2.81 at 5 years. In PWS-LS, BMI-SDS increased from 2.25 to 3.19 (ΔBMI-SDS% + 36.4%, P = .003). The mean number of obesity-related comorbidities decreased in PWS-LSG (2.69 ± 1.66 to 1.94 ± 1.18; P = .041) and in OB-LSG (1.25 ± 0.88 to 0.56 ± 0.76; P < .001), but increased in PWS-LS (1.56 ± 0.96 to 2.44 ± 1.32; P = .004). Conclusion: In PWS, LSG produces clinically relevant early weight loss with partial maintenance at 5 years, but markedly attenuated long-term benefit compared with non-syndromic peers. Nevertheless, when interpreted against the progressive worsening of obesity and cardiometabolic comorbidities observed with lifestyle intervention alone, LSG appears to modify disease trajectory in PWS.